Connection

James Ballenger to Humans

This is a "connection" page, showing publications James Ballenger has written about Humans.
Connection Strength

0.575
  1. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
    View in: PubMed
    Score: 0.012
  2. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs. 2007; 21(1):47-71.
    View in: PubMed
    Score: 0.011
  3. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004 Dec; 65(12):1696-707.
    View in: PubMed
    Score: 0.009
  4. Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 2004; 65 Suppl 1:55-62.
    View in: PubMed
    Score: 0.009
  5. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med. 2003 Apr; 33(3):511-8.
    View in: PubMed
    Score: 0.008
  6. A brief scale for assessing patients' satisfaction with care in outpatient psychiatric services. Psychiatr Serv. 2001 Jun; 52(6):816-9.
    View in: PubMed
    Score: 0.007
  7. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict. 2001; 10(s1):s16-s23.
    View in: PubMed
    Score: 0.007
  8. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001; 62 Suppl 11:53-8.
    View in: PubMed
    Score: 0.007
  9. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001; 62 Suppl 12:5-9.
    View in: PubMed
    Score: 0.007
  10. Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001; 62 Suppl 13:47-55.
    View in: PubMed
    Score: 0.007
  11. Consensus statement on depression, anxiety, and cardiovascular disease. J Clin Psychiatry. 2001; 62 Suppl 8:24-7.
    View in: PubMed
    Score: 0.007
  12. Consensus statement on depression, anxiety, and functional gastrointestinal disorders. J Clin Psychiatry. 2001; 62 Suppl 8:48-51.
    View in: PubMed
    Score: 0.007
  13. Consensus statement on depression, anxiety, and oncology. J Clin Psychiatry. 2001; 62 Suppl 8:64-7.
    View in: PubMed
    Score: 0.007
  14. Procedural and methodological issues in telepsychiatry research and program development. Psychiatr Serv. 2000 Dec; 51(12):1522-7.
    View in: PubMed
    Score: 0.007
  15. Structural issues and policy in the management of depressive illness. Overview and expert panel commentary. Eur Neuropsychopharmacol. 2000 Dec; 10 Suppl 4:S449-53.
    View in: PubMed
    Score: 0.007
  16. A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry. 2000 Nov 15; 48(10):962-70.
    View in: PubMed
    Score: 0.007
  17. Recognizing the patient with social anxiety disorder. Int Clin Psychopharmacol. 2000 Jul; 15 Suppl 1:S1-5.
    View in: PubMed
    Score: 0.007
  18. Vagus nerve stimulation: a new tool for brain research and therapy. Biol Psychiatry. 2000 Feb 15; 47(4):287-95.
    View in: PubMed
    Score: 0.007
  19. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2000; 61 Suppl 5:60-6.
    View in: PubMed
    Score: 0.007
  20. Current treatments of the anxiety disorders in adults. Biol Psychiatry. 1999 Dec 01; 46(11):1579-94.
    View in: PubMed
    Score: 0.006
  21. Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal period. Alcohol Clin Exp Res. 1999 Jun; 23(6):1077-84.
    View in: PubMed
    Score: 0.006
  22. Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1999; 60 Suppl 7:54-61.
    View in: PubMed
    Score: 0.006
  23. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999; 60 Suppl 22:29-34.
    View in: PubMed
    Score: 0.006
  24. Translational implications of the amygdala-stria terminalis model for the clinical anxiety disorders. Biol Psychiatry. 1998 Dec 15; 44(12):1204-7.
    View in: PubMed
    Score: 0.006
  25. Sleep Deprivation in social phobia and generalized anxiety disorder. Biol Psychiatry. 1998 Jun 01; 43(11):840-2.
    View in: PubMed
    Score: 0.006
  26. Comorbidity of panic and depression: implications for clinical management. Int Clin Psychopharmacol. 1998 Apr; 13 Suppl 4:S13-7.
    View in: PubMed
    Score: 0.006
  27. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998 Jan; 155(1):36-42.
    View in: PubMed
    Score: 0.006
  28. Treatment of panic disorder in the general medical setting. J Psychosom Res. 1998 Jan; 44(1):5-15.
    View in: PubMed
    Score: 0.006
  29. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998; 59 Suppl 8:47-54.
    View in: PubMed
    Score: 0.006
  30. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998; 59 Suppl 17:54-60.
    View in: PubMed
    Score: 0.006
  31. Sleep deprivation in panic disorder and obsessive-compulsive disorder. Can J Psychiatry. 1997 Nov; 42(9):982-3.
    View in: PubMed
    Score: 0.006
  32. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry. 1997 May; 154(5):700-2.
    View in: PubMed
    Score: 0.005
  33. Panic disorder in the medical setting. J Clin Psychiatry. 1997; 58 Suppl 2:13-7; discussion 18-9.
    View in: PubMed
    Score: 0.005
  34. Discussion and overview: what can we learn if we view panic disorder across the life span and across different presentations and contexts? Bull Menninger Clin. 1997; 61(2 Suppl A):A95-102.
    View in: PubMed
    Score: 0.005
  35. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol. 1996 Aug; 64(4):660-8.
    View in: PubMed
    Score: 0.005
  36. Clinical evaluation of venlafaxine. J Clin Psychopharmacol. 1996 Jun; 16(3 Suppl 2):29S-35S; discussion 35S-36S.
    View in: PubMed
    Score: 0.005
  37. Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull. 1996; 32(1):149-55.
    View in: PubMed
    Score: 0.005
  38. The DSM-IV panic disorder field trial: panic attack frequency and functional disability. Anxiety. 1996; 2(4):157-66.
    View in: PubMed
    Score: 0.005
  39. Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry. 1995 Nov; 152(11):1665-7.
    View in: PubMed
    Score: 0.005
  40. Sertraline in social phobia. J Clin Psychopharmacol. 1995 Oct; 15(5):372-3.
    View in: PubMed
    Score: 0.005
  41. CSF isatin is elevated in bulimia nervosa. Biol Psychiatry. 1995 Apr 01; 37(7):481-3.
    View in: PubMed
    Score: 0.005
  42. Panic disorder. Pathophysiology and drug treatment. Drugs. 1995 Mar; 49(3):328-44.
    View in: PubMed
    Score: 0.005
  43. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995 Mar; 56(3):118-21.
    View in: PubMed
    Score: 0.005
  44. Comorbidity of axis I psychiatric disorders in bulimia nervosa. J Clin Psychiatry. 1995 Feb; 56(2):77-80.
    View in: PubMed
    Score: 0.005
  45. Plasma pyridoxal phosphate in anxiety disorders. Biol Psychiatry. 1994 Nov 01; 36(9):606-8.
    View in: PubMed
    Score: 0.005
  46. Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biol Psychiatry. 1994 Sep 15; 36(6):425-7.
    View in: PubMed
    Score: 0.005
  47. Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. Am J Psychiatry. 1994 Jun; 151(6):930-2.
    View in: PubMed
    Score: 0.004
  48. Overview of panic disorder. Trans Am Clin Climatol Assoc. 1994; 105:36-51; discussion 51-3.
    View in: PubMed
    Score: 0.004
  49. Panic disorder and gastrointestinal symptoms: findings from the NIMH Epidemiologic Catchment Area project. Am J Psychiatry. 1994 Jan; 151(1):64-70.
    View in: PubMed
    Score: 0.004
  50. Medication discontinuation in panic disorder. J Clin Psychiatry. 1993 Oct; 54 Suppl:15-21; discussion 22-4.
    View in: PubMed
    Score: 0.004
  51. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry. 1993 Aug; 150(8):1216-8.
    View in: PubMed
    Score: 0.004
  52. CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. Am J Psychiatry. 1993 Jul; 150(7):1099-101.
    View in: PubMed
    Score: 0.004
  53. Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia. Br J Psychiatry. 1993 Jun; 162:788-9; discussion 790-4.
    View in: PubMed
    Score: 0.004
  54. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993 Jun; 54(6):224-8.
    View in: PubMed
    Score: 0.004
  55. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics. 1993 May-Jun; 34(3):229-34.
    View in: PubMed
    Score: 0.004
  56. Attending nurses. J Child Adolesc Psychiatr Ment Health Nurs. 1993 Apr-Jun; 6(2):38.
    View in: PubMed
    Score: 0.004
  57. Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res. 1993 Apr-Jun; 27(2):161-72.
    View in: PubMed
    Score: 0.004
  58. Examining criteria for panic disorder. Hosp Community Psychiatry. 1993 Mar; 44(3):226-8.
    View in: PubMed
    Score: 0.004
  59. Panic disorder: efficacy of current treatments. Psychopharmacol Bull. 1993; 29(4):477-86.
    View in: PubMed
    Score: 0.004
  60. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8.
    View in: PubMed
    Score: 0.004
  61. Tricyclic antidepressant triggers mania in patient with organic affective disorder. J Clin Psychiatry. 1992 Oct; 53(10):377-8.
    View in: PubMed
    Score: 0.004
  62. CSF beta-endorphin and dynorphin in bulimia nervosa. Am J Psychiatry. 1992 Aug; 149(8):1086-90.
    View in: PubMed
    Score: 0.004
  63. The effects of pregnancy on preexisting panic disorder. J Clin Psychiatry. 1992 Jun; 53(6):201-3.
    View in: PubMed
    Score: 0.004
  64. Blood groups in panic disorder. Am J Psychiatry. 1992 Mar; 149(3):410.
    View in: PubMed
    Score: 0.004
  65. Medication discontinuation in panic disorder. J Clin Psychiatry. 1992 Mar; 53 Suppl:26-31.
    View in: PubMed
    Score: 0.004
  66. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Adv Biochem Psychopharmacol. 1992; 47:431-47.
    View in: PubMed
    Score: 0.004
  67. Cardiovascular status of panic disorder patients with and without prominent cardiac symptoms. Psychosomatics. 1992; 33(1):81-4.
    View in: PubMed
    Score: 0.004
  68. Cocaine-induced psychosis. J Clin Psychiatry. 1991 Dec; 52(12):509-12.
    View in: PubMed
    Score: 0.004
  69. Irritable bowel syndrome in patients with panic disorder. Am J Psychiatry. 1991 Nov; 148(11):1614.
    View in: PubMed
    Score: 0.004
  70. Treatment of social phobia with bupropion. J Clin Psychopharmacol. 1991 Aug; 11(4):276-7.
    View in: PubMed
    Score: 0.004
  71. Fluoxetine treatment of voyeurism. Am J Psychiatry. 1991 Jul; 148(7):950.
    View in: PubMed
    Score: 0.004
  72. Effect of alprazolam on depression in panic disorder. J Clin Psychopharmacol. 1991 Apr; 11(2):145-6.
    View in: PubMed
    Score: 0.004
  73. Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry. 1991 Feb; 52 Suppl:18-23; discussion 24-5.
    View in: PubMed
    Score: 0.004
  74. Decisions for the clinician in the treatment of panic disorder: when to treat, which treatment to use, and how long to treat. J Clin Psychiatry. 1991 Feb; 52 Suppl:26-31; discussion 32.
    View in: PubMed
    Score: 0.004
  75. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull. 1991; 27(2):171-9.
    View in: PubMed
    Score: 0.004
  76. Pergolide mesylate treatment of cocaine withdrawal. J Clin Psychiatry. 1991 Jan; 52(1):39-40.
    View in: PubMed
    Score: 0.004
  77. Brain MRI in obsessive-compulsive disorder. Psychiatry Res. 1991 Jan; 36(1):45-9.
    View in: PubMed
    Score: 0.004
  78. Panic and phobic disorders in patients with obsessive compulsive disorder. J Clin Psychiatry. 1990 Nov; 51(11):456-8.
    View in: PubMed
    Score: 0.003
  79. Rapid response of patients simultaneously treated with lithium and nortriptyline. J Clin Psychiatry. 1990 Mar; 51(3):124-5.
    View in: PubMed
    Score: 0.003
  80. Efficacy of benzodiazepines in panic disorder and agoraphobia. J Psychiatr Res. 1990; 24 Suppl 2:15-25.
    View in: PubMed
    Score: 0.003
  81. Phenelzine treatment of panic disorder: lack of effect on pyridoxal phosphate levels. J Clin Psychopharmacol. 1989 Dec; 9(6):428-31.
    View in: PubMed
    Score: 0.003
  82. Depression in patients receiving lorazepam for panic. Am J Psychiatry. 1989 Sep; 146(9):1230-1.
    View in: PubMed
    Score: 0.003
  83. Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment. J Clin Psychiatry. 1989 Sep; 50(9):356-7.
    View in: PubMed
    Score: 0.003
  84. Three cases of panic disorder with agoraphobia in children. Am J Psychiatry. 1989 Jul; 146(7):922-4.
    View in: PubMed
    Score: 0.003
  85. Toward an integrated model of panic disorder. Am J Orthopsychiatry. 1989 Apr; 59(2):284-93.
    View in: PubMed
    Score: 0.003
  86. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70.
    View in: PubMed
    Score: 0.003
  87. Electroencephalography during sleep of patients with panic disorder. J Neuropsychiatry Clin Neurosci. 1989; 1(4):372-6.
    View in: PubMed
    Score: 0.003
  88. Recent advances in the psychopharmacological treatment of anxiety disorders. Hosp Community Psychiatry. 1988 Nov; 39(11):1157-65.
    View in: PubMed
    Score: 0.003
  89. The use of anticonvulsants in manic-depressive illness. J Clin Psychiatry. 1988 Nov; 49 Suppl:21-5.
    View in: PubMed
    Score: 0.003
  90. Possible relationship of bowel obsessions to panic disorder with agoraphobia. Am J Psychiatry. 1988 Oct; 145(10):1324-5.
    View in: PubMed
    Score: 0.003
  91. Decentralized services for public hospital patients: a cost analysis. Hosp Community Psychiatry. 1988 Aug; 39(8):827-9.
    View in: PubMed
    Score: 0.003
  92. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May; 45(5):413-22.
    View in: PubMed
    Score: 0.003
  93. The clinical use of carbamazepine in affective disorders. J Clin Psychiatry. 1988 Apr; 49 Suppl:13-21.
    View in: PubMed
    Score: 0.003
  94. Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988 Mar 01; 23(5):507-14.
    View in: PubMed
    Score: 0.003
  95. Precursor amino acid concentrations in normal weight bulimics and normal controls. Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12(6):893-8.
    View in: PubMed
    Score: 0.003
  96. Alprazolam in the treatment of social phobia. J Clin Psychiatry. 1988 Jan; 49(1):17-9.
    View in: PubMed
    Score: 0.003
  97. Unrecognized prevalence of panic disorder in primary care, internal medicine and cardiology. Am J Cardiol. 1987 Dec 28; 60(18):39J-47J.
    View in: PubMed
    Score: 0.003
  98. Antidepressants in panic disorder and agoraphobia. J Affect Disord. 1987 Sep-Oct; 13(2):153-68.
    View in: PubMed
    Score: 0.003
  99. Sexual side effects of alprazolam. Am J Psychiatry. 1987 Feb; 144(2):254-5.
    View in: PubMed
    Score: 0.003
  100. The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. CNS Spectr. 2006 Oct; 11(10):788-99.
    View in: PubMed
    Score: 0.003
  101. Can panic disorder present as irritable bowel syndrome? J Clin Psychiatry. 1986 Sep; 47(9):470-3.
    View in: PubMed
    Score: 0.003
  102. Conditioning and sensitisation in the longitudinal course of affective illness. Br J Psychiatry. 1986 Aug; 149:191-201.
    View in: PubMed
    Score: 0.003
  103. Pharmacotherapy of the panic disorders. J Clin Psychiatry. 1986 Jun; 47 Suppl:27-32.
    View in: PubMed
    Score: 0.003
  104. Biological aspects of panic disorder. Am J Psychiatry. 1986 Apr; 143(4):516-8.
    View in: PubMed
    Score: 0.003
  105. CSF somatostatin in affective illness and normal volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 1985; 9(4):393-400.
    View in: PubMed
    Score: 0.002
  106. Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport. 2004 Dec 22; 15(18):2701-5.
    View in: PubMed
    Score: 0.002
  107. Psychopharmacology of the anxiety disorders. Psychiatr Clin North Am. 1984 Dec; 7(4):757-71.
    View in: PubMed
    Score: 0.002
  108. Tricyclic antidepressant use in a patient with bundle branch blocks and ventricular ectopy. J Clin Psychiatry. 1984 Aug; 45(8):353-5.
    View in: PubMed
    Score: 0.002
  109. The efficacy of carbamazepine in affective illness. Adv Biochem Psychopharmacol. 1984; 39:421-37.
    View in: PubMed
    Score: 0.002
  110. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull. 1984; 20(3):572-84.
    View in: PubMed
    Score: 0.002
  111. Bupropion sustained release for panic disorder. Psychopharmacol Bull. 2003; 37(4):66-72.
    View in: PubMed
    Score: 0.002
  112. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol. 2002 Dec; 5(4):315-25.
    View in: PubMed
    Score: 0.002
  113. The "atypical" clinical picture of adolescent mania. Am J Psychiatry. 1982 May; 139(5):602-6.
    View in: PubMed
    Score: 0.002
  114. Vagus nerve stimulation. A potential therapy for resistant depression? Psychiatr Clin North Am. 2000 Dec; 23(4):757-83.
    View in: PubMed
    Score: 0.002
  115. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 1980 Jul; 137(7):782-90.
    View in: PubMed
    Score: 0.002
  116. Bupropion-SR in treatment of social phobia. Depress Anxiety. 2000; 12(2):111-3.
    View in: PubMed
    Score: 0.002
  117. Headaches after lumbar puncture and insensitivity to pain in psychiatric patients. N Engl J Med. 1979 Jul 12; 301(2):110.
    View in: PubMed
    Score: 0.002
  118. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999 Jul; 60(7):427-35.
    View in: PubMed
    Score: 0.002
  119. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. J Clin Psychiatry. 1999 May; 60(5):299-301.
    View in: PubMed
    Score: 0.002
  120. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry. 1979 Feb; 36(2):224-7.
    View in: PubMed
    Score: 0.002
  121. Feasibility of using fMRI to study mothers responding to infant cries. Depress Anxiety. 1999; 10(3):99-104.
    View in: PubMed
    Score: 0.002
  122. Panic disorder and quality of life: variables predictive of functional impairment. Am J Psychiatry. 1997 Jun; 154(6):766-72.
    View in: PubMed
    Score: 0.001
  123. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997; 58 Suppl 11:11-8.
    View in: PubMed
    Score: 0.001
  124. Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry. 1996 Dec; 57(12):576-8.
    View in: PubMed
    Score: 0.001
  125. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry. 1996 Apr 15; 39(8):703-7.
    View in: PubMed
    Score: 0.001
  126. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94.
    View in: PubMed
    Score: 0.001
  127. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995 Apr 01; 37(7):462-6.
    View in: PubMed
    Score: 0.001
  128. Infrequent panic attacks: psychiatric comorbidity, personality characteristics and functional disability. J Psychiatr Res. 1995 Mar-Apr; 29(2):121-31.
    View in: PubMed
    Score: 0.001
  129. A community-based public-academic liaison program. Am J Psychiatry. 1994 Aug; 151(8):1181-7.
    View in: PubMed
    Score: 0.001
  130. Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord. 1994 Jan; 30(1):5-13.
    View in: PubMed
    Score: 0.001
  131. Electroconvulsive therapy and cardiac pacemakers. Psychosomatics. 1973 Jul-Aug; 14(4):233-4.
    View in: PubMed
    Score: 0.001
  132. Cerebrospinal fluid thyrotropin-releasing hormone concentrations in patients with anxiety disorders. J Neuropsychiatry Clin Neurosci. 1993; 5(3):335-7.
    View in: PubMed
    Score: 0.001
  133. Eating disorders and social phobia. Arch Gen Psychiatry. 1993 Jan; 50(1):70.
    View in: PubMed
    Score: 0.001
  134. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry. 1992 Nov; 149(11):1556-62.
    View in: PubMed
    Score: 0.001
  135. CSF diazepam-binding inhibitor concentrations in panic disorder. Biol Psychiatry. 1992 Oct 15; 32(8):712-6.
    View in: PubMed
    Score: 0.001
  136. Discontinuation of alprazolam after long-term treatment of panic-related disorders. J Clin Psychopharmacol. 1992 Oct; 12(5):352-4.
    View in: PubMed
    Score: 0.001
  137. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 1992 May; 149(5):691-3.
    View in: PubMed
    Score: 0.001
  138. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992 Apr; 12(2):96-103.
    View in: PubMed
    Score: 0.001
  139. CSF opioids in panic disorder. Biol Psychiatry. 1991 Sep 01; 30(5):512-4.
    View in: PubMed
    Score: 0.001
  140. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991 Aug 01; 30(3):225-32.
    View in: PubMed
    Score: 0.001
  141. Cocaine abuse among schizophrenic patients. Am J Psychiatry. 1990 Sep; 147(9):1164-7.
    View in: PubMed
    Score: 0.001
  142. CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity. Am J Psychiatry. 1990 Feb; 147(2):225-9.
    View in: PubMed
    Score: 0.001
  143. Early family experiences of women with bulimia and depression. Arch Psychiatr Nurs. 1990 Feb; 4(1):43-52.
    View in: PubMed
    Score: 0.001
  144. Sequence of improvement in agoraphobia with panic attacks. J Psychiatr Res. 1990; 24(1):1-8.
    View in: PubMed
    Score: 0.001
  145. CSF prostaglandin-E in agoraphobia with panic attacks. Biol Psychiatry. 1989 Jul; 26(3):257-64.
    View in: PubMed
    Score: 0.001
  146. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989 May; 146(5):617-21.
    View in: PubMed
    Score: 0.001
  147. Secondary depression in panic disorder and agoraphobia. II. Dimensions of depressive symptomatology and their response to treatment. J Affect Disord. 1989 Jan-Feb; 16(1):49-58.
    View in: PubMed
    Score: 0.001
  148. Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. J Behav Ther Exp Psychiatry. 1988 Jun; 19(2):119-26.
    View in: PubMed
    Score: 0.001
  149. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry. 1988 May; 45(5):423-8.
    View in: PubMed
    Score: 0.001
  150. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry. 1987 May; 144(5):664-5.
    View in: PubMed
    Score: 0.001
  151. The effects of lithium on neuroendocrine function in affectively ill patients. Acta Psychiatr Scand. 1986 May; 73(5):524-8.
    View in: PubMed
    Score: 0.001
  152. Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness. Arch Gen Psychiatry. 1986 Apr; 43(4):392-6.
    View in: PubMed
    Score: 0.001
  153. Neuroendocrine effects of carbamazepine in patients with affective illness. Epilepsia. 1986 Mar-Apr; 27(2):156-60.
    View in: PubMed
    Score: 0.001
  154. Neuroendocrine effects of the dopamine agonist piribedil in depressed patients. Clin Neuropharmacol. 1986; 9(5):448-55.
    View in: PubMed
    Score: 0.001
  155. The dexamethasone suppression test in agoraphobia. J Clin Psychopharmacol. 1985 Apr; 5(2):100-2.
    View in: PubMed
    Score: 0.001
  156. Effects of carbamazepine on cerebrospinal fluid somatostatin. Psychopharmacology (Berl). 1985; 85(2):210-3.
    View in: PubMed
    Score: 0.001
  157. Effects of carbamazepine on noradrenergic mechanisms in affectively ill patients. Psychopharmacology (Berl). 1985; 87(1):59-63.
    View in: PubMed
    Score: 0.001
  158. The neurobiology of some dimensions of personality. Int Rev Neurobiol. 1984; 25:391-436.
    View in: PubMed
    Score: 0.001
  159. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry. 1983 Dec; 140(12):1602-4.
    View in: PubMed
    Score: 0.001
  160. Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation. J Clin Endocrinol Metab. 1983 Nov; 57(5):952-7.
    View in: PubMed
    Score: 0.001
  161. Tetrahydrobiopterin levels in cerebrospinal fluid of affectively ill patients. Lancet. 1983 Jul 02; 2(8340):55-6.
    View in: PubMed
    Score: 0.001
  162. CSF dopamine beta-hydroxylase in schizophrenia. Arch Gen Psychiatry. 1983 Jul; 40(7):743-7.
    View in: PubMed
    Score: 0.001
  163. Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. Arch Gen Psychiatry. 1983 Jun; 40(6):673-6.
    View in: PubMed
    Score: 0.001
  164. Carbamazepine in alcohol withdrawal syndromes: relationship to the kindling model. J Clin Psychopharmacol. 1983 Jun; 3(3):204-5.
    View in: PubMed
    Score: 0.001
  165. CSF somatostatin in affective illness. Arch Gen Psychiatry. 1983 Apr; 40(4):409-12.
    View in: PubMed
    Score: 0.001
  166. The effect of lithium on the osmoregulation of arginine vasopressin secretion. J Clin Endocrinol Metab. 1983 Feb; 56(2):295-9.
    View in: PubMed
    Score: 0.001
  167. Biochemical effects of carbamazepine: relationship to its mechanisms of action in affective illness. Prog Neuropsychopharmacol Biol Psychiatry. 1983; 7(2-3):263-71.
    View in: PubMed
    Score: 0.001
  168. Cerebrospinal fluid somatostatin in primary affective disorder. Psychopharmacol Bull. 1983; 19(3):422-5.
    View in: PubMed
    Score: 0.001
  169. Neurohypophyseal function in affective illness. Psychopharmacol Bull. 1983; 19(3):426-31.
    View in: PubMed
    Score: 0.001
  170. Kindling and carbamazepine in affective illness. J Nerv Ment Dis. 1982 Dec; 170(12):717-31.
    View in: PubMed
    Score: 0.000
  171. A conjoint psychiatry-internal medicine program: development of a teaching and clinical model. Am J Psychiatry. 1982 Nov; 139(11):1437-42.
    View in: PubMed
    Score: 0.000
  172. Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness. Biol Psychiatry. 1982 Sep; 17(9):1037-45.
    View in: PubMed
    Score: 0.000
  173. Peptides in the cerebrospinal fluid of neuropsychiatric patients: an approach to central nervous system peptide function. Life Sci. 1982 Jul 05; 31(1):1-15.
    View in: PubMed
    Score: 0.000
  174. Cerebrospinal fluid hydroxylase cofactor in schizophrenia. Psychiatry Res. 1982 Apr; 6(2):145-51.
    View in: PubMed
    Score: 0.000
  175. Central nervous system gamma-aminobutyric acid activity in man. Relationship to age and sex as reflected in CSF. Arch Neurol. 1982 Apr; 39(4):247-9.
    View in: PubMed
    Score: 0.000
  176. Endorphins in the cerebrospinal fluid of psychiatric patients. Ann N Y Acad Sci. 1982; 398:399-412.
    View in: PubMed
    Score: 0.000
  177. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry. 1981 Dec; 38(12):1315-7.
    View in: PubMed
    Score: 0.000
  178. Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. Am J Psychiatry. 1981 Nov; 138(11):1457-62.
    View in: PubMed
    Score: 0.000
  179. Effect of carbamazepine on CSF opioid activity; relationship to antidepressant response. Psychiatry Res. 1981 Aug; 5(1):59-66.
    View in: PubMed
    Score: 0.000
  180. Relationship between urinary free cortisol and CSF opioid binding activity in depressed patients and normal volunteers. Psychiatry Res. 1981 Aug; 5(1):87-93.
    View in: PubMed
    Score: 0.000
  181. The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry. 1981 Aug; 138(8):1045-50.
    View in: PubMed
    Score: 0.000
  182. Slow and rapid onset of manic episodes: implications for underlying biology. Psychiatry Res. 1981 Apr; 4(2):229-37.
    View in: PubMed
    Score: 0.000
  183. Effects of vasopressin on human memory functions. Science. 1981 Feb 06; 211(4482):601-3.
    View in: PubMed
    Score: 0.000
  184. Cerebrospinal fluid amine metabolites and cyclic nucleotides in human aggression [proceedings]. Psychopharmacol Bull. 1981 Jan; 17(1):63-5.
    View in: PubMed
    Score: 0.000
  185. Plasma and CSF MHPG in normals [proceedings]. Psychopharmacol Bull. 1981 Jan; 17(1):86-7.
    View in: PubMed
    Score: 0.000
  186. Measurement of endorphins in CSF. Relationship to psychiatric diagnosis. Mod Probl Pharmacopsychiatry. 1981; 17:246-62.
    View in: PubMed
    Score: 0.000
  187. Lack of effect of carbamazepine on gamma-aminobutyric acid in cerebrospinal fluid. Neurology. 1980 Sep; 30(9):1008-11.
    View in: PubMed
    Score: 0.000
  188. Immunoreactive calcitonin in cerebrospinal fluid of man. Brain Res. 1980 Aug 04; 194(2):598-602.
    View in: PubMed
    Score: 0.000
  189. Rapid mood cycling and concomitant cortisol changes produced by cyproheptadine. Am J Psychiatry. 1980 Mar; 137(3):378-9.
    View in: PubMed
    Score: 0.000
  190. Dopamine beta-hydroxylase in CSF. Relationship to personality measures. Arch Gen Psychiatry. 1980 Mar; 37(3):308-10.
    View in: PubMed
    Score: 0.000
  191. Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science. 1980 Jan 18; 207(4428):331-3.
    View in: PubMed
    Score: 0.000
  192. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980 Jan; 37(1):51-9.
    View in: PubMed
    Score: 0.000
  193. Effects of 1-desamo-8-D-arginine vasopressin on behaviour and cognition in primary affective disorder. Lancet. 1979 Nov 10; 2(8150):992-4.
    View in: PubMed
    Score: 0.000
  194. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res. 1979 Oct; 1(2):131-9.
    View in: PubMed
    Score: 0.000
  195. gamma-Aminobutyric acid in human cerebrospinal fluid: normal values. Lancet. 1979 Sep 08; 2(8141):534-5.
    View in: PubMed
    Score: 0.000
  196. Low cerebrospinal fluid gamma-aminobutyric acid content in seizure patients. Neurology. 1979 Sep; 29(9 Pt 1):1203-8.
    View in: PubMed
    Score: 0.000
  197. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry. 1979 Apr; 14(2):337-44.
    View in: PubMed
    Score: 0.000
  198. Dopamine-beta-hydroxylase in the cerebrospinal fluid of psychiatric patients. Biol Psychiatry. 1978 Dec; 13(6):685-94.
    View in: PubMed
    Score: 0.000
  199. Cerebrospinal fluid homovanillic acid in male alcoholics: effects of disulfiram. Biol Psychiatry. 1977 Oct; 12(5):635-42.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.